Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Do Anti-Nausea Meds Work in Myeloma?
Do Anti-Nausea Meds Work in Myeloma?
Do anti-nausea meds work in myeloma? Only about a third of the time, according to the research below. A stem cell transplant is an aggressive treatment with a lot of chemotherapy. Nausea is a common side effect.
Consider taking an integrative approach to manage your chemotherapy-induced nausea. Ask your oncologist, for example, if adding ginger (tea, chews, ale, etc.) to conventional nausea treatments is okay.
Home remedies for managing chemo-induced nausea and vomiting
Home Remedies for Cancer Treatment-Induced Nausea
If you have any sort of pre-existing heart problems, remember that Zofran is cardiotoxic. Ask your oncologist about this, too.
Remember that nausea is common but is often minimized. In my experience, there is no side effect that can cause misery in the MM patient undergoing an autologous stem cell transplant.
Scroll down the page, post a comment or question if you are considering undergoing an ASCT. I will reply to you ASAP.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Effectiveness of antiemetic regimens in controlling chemotherapy induced nausea and vomiting during hematopoietic stem cell transplantation
Abstract
This study aimed to evaluate the efficacy of antiemetic regimens in controlling chemotherapy-induced nausea and vomiting (CINV) among patients with haematological malignancies undergoing highly (HEC) or moderately emetogenic chemotherapy (MEC) as part of conditioning for hematopoietic stem cell transplantation (HSCT).
Effectiveness was measured by complete response (CR) and complete protection (CP) from nausea/emesis across acute (chemotherapy days) and delayed (five days post-chemotherapy) phases.
Bitherapy (5HT3 receptor antagonists + corticosteroids) and monotherapy regimens were compared. 112 patients were included.
Of 102 analysed patients, CR and CP were achieved in 42.1% and 34.3% of patients in the acute phase, and 33.3% and 30.4% in the delayed phase, respectively.
Patients receiving bitherapy (who received myeloablative conditioning regimens and high-emetogenic regimens) achieved better CINV control compared to those treated with monotherapy (who received reduced-intensity and moderate emetogenic treatments).
With significant improvements in acute CR (p = 0.0003) and CP (p = 0.001). Additionally, Rescue antiemetic use was lower in the bitherapy group (p = 0.230). This study reinforces the importance of assessment of antiemetic response in these patients and highlights the effectiveness of bitherapy with 5HT3 receptor antagonists and corticosteroids. However, our findings also suggest that antiemetic regimens could be optimised with strategies possibly involving triple therapy or the integration of other agents…
The most prevalent diseases were Multiple Myeloma (MM) in 32.1%, followed by Acute Myeloid Leukemia (AML) in 18.8%, Diffuse Large B-Cell Lymphoma (DLBCL) in 10.7%, and Hodgkin Lymphoma (LH) in 7.1%. Autologous transplants were performed in 53.6% of cases.
The most common conditioning regimens were thiotepa/busulfan/fludarabine regimen (TBF) (34.8%) and melphalan 200 mg/m2 (23.2%). 54.5% of patients received combination therapy with 5HT3 receptor antagonists and corticosteroids, while 45.5% received monotherapy with the first. In addition, 64.3% of the regimens had high emetogenic potential…
CR and CP rates indicate that monotherapy may be insufficient for CINV control in high-risk patients, underscoring the need for robust multi-agent regimens. The results showed that more patients achieved CR in the acute phase than in the delayed phase. CP was similar in both phases, at around 30%. Patients receiving bitherapy were associated with better control of CINV. The results suggest the inadequacy of monotherapy and that the addition of corticosteroids, especially in the acute phase, should improve CINV, even in patients undergoing emetogenic regimens with less emetogenic potential (MEC), and highlight the need to establish more robust antiemetic strategies…
Conclusion
This study reinforces the need to assess antiemetic response in patients undergoing transplantation and highlights the importance of the addition of corticosteroids to antiemetic therapy. However, our findings clearly demonstrate the insufficiency of the antiemetic strategies currently used, particularly single-agent or biotherapy, to achieve optimal control of CINV in this high-risk population, highlighting the necessity for enhanced approaches, including triple therapy or the integration of newer agents such as olanzapine.
Future research should prioritize optimizing antiemetic regimens for HSCT patients, with an emphasis on multicenter studies to enhance the generalizability of these findings.
Do anti-nausea meds work in myeloma Do anti-nausea meds work in myeloma Do anti-nausea meds work in myeloma